Do you gain weight back after stopping Wegovy?

Why does weight come back when semaglutide stops?

Semaglutide works by activating GLP-1 receptors in the brain and gut, dampening hunger signals, slowing gastric emptying and increasing the sensation of fullness. The result (eating less, feeling satisfied sooner) depends on the medicine being present and active in your system. When the last dose clears, those effects clear with it.

That is not a failure of willpower. Obesity involves persistent changes to appetite-regulating hormones: leptin, ghrelin and others continue signalling in ways that drive eating above maintenance level even after substantial weight loss. Semaglutide partially corrects that biology while you take it. Stopping is, physiologically speaking, similar to removing any other long-term medicine for a chronic condition, the underlying biology reasserts itself.

The NHS medicines page for semaglutide explains clearly that treatment is intended to run alongside a reduced-calorie diet and increased activity, those two elements do not simply evaporate on stopping, but they rarely provide enough metabolic counterweight on their own once the pharmacological support is gone. The practical upshot is that regain is common, partial, and biology-driven rather than behavioural.

How much weight do people typically regain, and how quickly?

The clearest UK-relevant evidence comes from the STEP 1 trial extension, published in the New England Journal of Medicine. Participants who had lost an average of around 15% body weight over 68 weeks of semaglutide 2.4mg then entered a one-year observation period without the medicine. By the end of that year, roughly two-thirds of the lost weight had returned.

A few things are worth understanding about that figure. First, some net benefit remained: participants were still, on average, lighter than at baseline, though the gap was narrowing. Second, cardiometabolic improvements (blood pressure, blood glucose, lipids) that had appeared during treatment also partially reversed during regain. Third, regain was not uniform: people who had made more durable changes to dietary patterns and physical activity tended to hold slightly more of their loss, but no lifestyle subgroup was fully protected from the rebound.

If you are weighing up the cost of ongoing treatment against stopping, this evidence is directly relevant, the financial decision and the clinical decision are genuinely intertwined.

Some people also notice regain starting within a few weeks of their last dose. That reflects the medicine's half-life of about one week: by week four, very little active semaglutide remains. Hunger does not wait for a psychological adjustment period.

Is regain inevitable, or are there ways to reduce it?

Regain is common, not universal, and its scale varies. The honest answer, though, is that lifestyle changes alone are rarely enough to hold most of the ground gained, that is what the biology tells us, and pretending otherwise does readers no favours.

What the evidence does support is that certain factors are associated with holding more weight loss after stopping. Sustained higher levels of physical activity, particularly resistance training that preserves muscle mass, seem to matter. Protein adequacy during treatment helps maintain lean body mass, which in turn supports a higher resting metabolism. And patients who used the treatment period to build genuine, habitual changes (rather than relying entirely on reduced appetite to guide eating) appear to fare somewhat better.

For patients considering whether to stop at all, a related question is whether a planned pause or a gradual dose reduction produces different outcomes to abrupt cessation. That is an area of active research; current guidance from NHS England's weight-management injections page recommends discussing continuation with your clinical team rather than stopping unilaterally. The question of how long to stay on treatment is one our prescribers at the nume clinical team, sorry, at the nume

Let us try that differently. For patients considering whether to stop at all, the clinical conversation should include what stopping actually means biologically. Our prescribers at nume review every repeat order individually; if your circumstances change, that is the conversation to have with your clinical team.

There is also evidence that restarting semaglutide after a break can recapture a significant portion of lost weight, though restarting typically means returning to a lower dose and re-titrating under clinical supervision. If you stopped and regained, that is a clinically recognised pattern, not a reason to feel you have failed.

What does this mean for decisions about starting or continuing Wegovy?

If you are reading this before starting, it is worth knowing that the evidence supports Wegovy as an effective long-term medicine rather than a short-term course. Many people and their clinicians plan for ongoing treatment, with regular reviews. The Wegovy treatment overview covers how the titration schedule and clinical reviews work in practice at nume.

If you stopped and are trying to manage regain now, practical guidance on reducing weight regain after Wegovy covers the lifestyle and clinical options in more detail. And if you are weighing whether semaglutide is the right choice compared with other licensed treatments, the semaglutide information page explains the full picture including how it compares with tirzepatide.

If your question is specifically about the period immediately after stopping, what to expect after Wegovy goes deeper into the timeline and practical steps. For the broader question of what stopping semaglutide means for weight, regain after stopping semaglutide covers the mechanism and evidence in fuller detail.

We know it is frustrating to read that a medicine you may have worked hard to get access to cannot simply be stopped without consequence. That frustration is entirely reasonable. If you would like to discuss your options with a prescriber, you can check your eligibility for a free consultation and have your situation reviewed the same day by a real clinician, not a triage algorithm.